ClinicalTrials.gg
RecruitingNCT05037968PRECISEUpdated Oct 19, 2026

MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion

An interventional study of MagnetOs Flex Matrix and Trinity Elite in Degenerative Disc Disease, Spine Fusion and Leg Pain and/or Back Pain, sponsored by Kuros Biosurgery AG. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 19, 2026Study contact changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
47th of 141
100 · median 57
Started
2024
with 9 others
No phase
90 of 232
15 open now
Primary completion
2026-12
later than 23 of 57 live
Registered
183rd of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 47th largest by planned enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2024, is one of 90 with no phase, reaches primary completion later than 23 of the 57 other live ones, and was the 183rd registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and undergoing spinal fusion surgery.

In this study, MagnetOs Flex Matrix will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.

Trinity Elite will also be used according to its latest IFU approved in the US. Specifically, this cellular based allograft is an allograft intended for the treatment of musculoskeletal defects.

Read the detailed description

In this study, following a screening period of a maximum of 30 days, 100 patients will undergo up to four-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Flex Matrix on the assigned side of the spine and Trinity Elite on the other at the diseased levels. They will be followed up at discharge, Week 2, Week 6, Month 3, Month 6, and Month 12. The primary endpoint will be analyzed at Month 12.

In this study, MagnetOs Flex Matrix will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Flex Matrix will be used as a bone graft extender mixed with autograft in a 1:1 vol% in patients with leg pain, and/or back pain requiring up to four-level instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.

Radiographs will be obtained at Screening, Week 2, Week 6, Month 3, Month 6 and Month 12. CT-scans will only be obtained at Month 6 and Month 12.

03

Conditions studied

  • Degenerative Disc Disease
  • Spine Fusion
  • Leg Pain and/or Back Pain

Keywords

  • Degenerative Disc Disease
  • Spine Fusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is able to read/be read, understand, and provide written and has signed the Review Board (IRB) approved informed consent.
  • Male or female patient ≥ 18 years old.
  • Patients with leg pain, and/or back pain requiring up to four-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1)
  • Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  • Requires > four-level fusion or expected to need secondary intervention within one year following surgery.
  • Had prior PLF fusion or attempted PLF fusion at the involved levels
  • Had previous decompression at the involved levels.
  • Women who are or intend to become pregnant within the next 12 months
  • To treat conditions in which general bone grafting is not advisable.
  • In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g., defect site stabilization is not possible).
  • In case of significant vascular impairment proximal to the graft site.
  • In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta or Paget's Disease) that affect bone or wound healing.
  • In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  • When intraoperative soft tissue coverage is not planned or possible.
  • Receiving treatment with medication interfering with calcium metabolism.
  • Had leg pain, and/or back pain related to a benign or malignant tumor.
  • Had history or presence of active .
  • Has known substance abuse, psychiatric disorder, or condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  • Is involved in active litigation relating to his/her spinal condition.
  • Has participated in an study within 30 days prior to surgery for study devices.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    MagnetOs Flex Matrix

    MagnetOs Flex Matrix use in instrumented posterolateral fusion, 5cc-10cc mixed with local autograft bone in a 1:1 ratio per spine level at the randomized assigned side

    Device: MagnetOs Flex Matrix

  • Active comparator
    Trinity Elite

    Trinity Elite is a cryopreserved, viable cellular allograft containing cancellous bone and demineralized cortical bone designed for surgical use, applied per spine level at the contralateral side. Trinity Elite will be used as a bone graft extender (mixed with local autograft)

    Device: Trinity Elite

Interventions

  • DeviceMagnetOs Flex Matrix

    Procedure: Instrumented Posterolateral Lumbar Fusion

  • DeviceTrinity Elite

    Procedure: Instrumented Posterolateral Lumbar Fusion

06

What researchers measure

Primary outcomes

  1. Radiographic Fusion by CT Scan

    The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

    Time frame: Month 12

Secondary outcomes

  1. Radiographic Fusion by Plain Radiographs

    The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs.

    Time frame: Month 6 and Month 12

  2. Radiographic Fusion by CT Scan

    The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

    Time frame: Month 6

  3. Functional Outcome by Oswestry Disability Index

    Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability.

    Time frame: Screening, Week 2, Week 6, Month 3, Month 6, Month 12

  4. Back and Leg Pain by Visual Analog Pain Scale (VAS)

    Change in back and leg pain using Visual Analog Pain Scale score. The patient completed questionnaire is a unidimensional measure of pain intensity using a continuous scale comprised of a horizontal line 10 centimeters (100 mm) in length. The line is anchored by "no pain" (score of 0) and "worst imaginable pain". A higher score indicates greater pain intensity.

    Time frame: Screening, Week 2, Week 6, Month 3, Month 6, and Month 12

  5. Neurologic Status by Physical Exam

    Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise.

    Time frame: Screening, Week 2, Week 6, Month 3, Month 6, and Month 12

  6. Success Rate

    Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery.

    Time frame: Week 2, Week 6, Month 3, Month 6, and Month12

Other outcomes

  1. Safety Endpoint - number of patients with Adverse Events

    The number of patients with Adverse Events from Screening up to Month 12 after surgery.

    Time frame: Screening up to 12 Months post-op

  2. Safety Endpoint - number of patients with Serious Adverse Events

    The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery

    Time frame: Screening up to 12 Months post-op

  3. Safety Endpoint - number of patients with Adverse Device Effects

    The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery.

    Time frame: 12 Months

  4. Safety Endpoint - number of patients with Device Related Complications

    The number of patients with any complications considered to device related with 12 months after surgery.

    Time frame: 12 Months

  5. Health Economic - Duration of Surgery

    Duration of surgery in minutes.

    Time frame: 12 Months

  6. Health Economic - Duration of Hospitalization

    Duration of hospital stay in days.

    Time frame: 12 Months

  7. Health Economic - Return to Work

    Time to return to work in days.

    Time frame: 12 Months

  8. Health Economic - Quality of Life

    Change in Quality of Life measurement using EuroQol-5D/5L scoring

    Time frame: 12 Months

07

Study locations

9 of 9 sites recruiting
  • Hartford Hospital
    Hartford, Connecticut 06106, United States
    Recruiting
    • Cameron Kia, MD · Principal investigator
  • Central CT Neurosurgery & Spine
    New Britain, Connecticut 06051, United States
    Recruiting
    • Ahmed Khan, MD · Principal investigator
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
    • Kern Singh, MD · Principal investigator
  • MedStar Health Research Institute
    Columbia, Maryland 21044, United States
    Recruiting
    • Addisu Mesfin, MD · Principal investigator
  • Michigan Orthopedic Surgeons
    Bloomfield Hills, Michigan 48033, United States
    Recruiting
    • Daniel Park, MD · Principal investigator
  • Pinehurst Surgical Clinic
    Pinehurst, North Carolina 28374, United States
    Recruiting
    • Daniel Williams, MD · Principal investigator
  • The Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
    • Stephanus Viljoen, MD · Principal investigator
  • Huntsman Spinal Clinic
    Salt Lake City, Utah 84124, United States
    Recruiting
    • Kade Huntsman, MD · Principal investigator
  • Inova Healthcare
    Fairfax, Virginia 22031, United States
    Recruiting
    • Andrew Fanous, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 30 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 8, 2021
StartActual
Jun 10, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Central CT Neurosurgery & Spine · New Britain, United States
Oct 19, 2026
Contact
Study contact changed: c•••@kurosbio.com · •••6793→c•••@kurosbio.com · •••6793. See the current contact
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added
    Show site
    • Central CT Neurosurgery & Spine · New Britain, United States
    Contact Study contact changed: c•••@kurosbio.com · •••6793→c•••@kurosbio.com · •••6793. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05037968
Lead sponsor
Kuros Biosurgery AG
Collaborators
Kuros BioSciences B.V.
Responsible party
Sponsor
First posted
Sep 8, 2021
Start date
Jun 10, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 19, 2026

Study contacts

Cesar Silva
Contact
cesar.silva@kurosbio.com
9702156793

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion